絞り込み

16602

広告

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis.

著者 Suzuki A , Yamada R , Chang X , Tokuhiro S , Sawada T , Suzuki M , Nagasaki M , Nakayama-Hamada M , Kawaida R , Ono M , Ohtsuki M , Furukawa H , Yoshino S , Yukioka M , Tohma S , Matsubara T , Wakitani S , Teshima R , Nishioka Y , Sekine A , Iida A , Taka
Nat Genet.2003 Aug ; 34(4):395-402.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

Laboratory for Rheumatic Diseases, SNP Research Center, The Institute of Physical and Chemical Research (RIKEN), 1-7-22, Suehirocho, Tsurumi-ku, Yokohama City, Kanagawa 230-0045, Japan.

スターを付ける スターを付ける     (487view , 0users)

Full Text Sources

Medical

Miscellaneous

Other Literature Sources

Individuals with rheumatoid arthritis frequently have autoantibodies to citrullinated peptides, suggesting the involvement of the peptidylarginine deiminases citrullinating enzymes (encoded by PADI genes) in rheumatoid arthritis. Previous linkage studies have shown that a susceptibility locus for rheumatoid arthritis includes four PADI genes but did not establish which PADI gene confers susceptibility to rheumatoid arthritis. We used a case-control linkage disequilibrium study to show that PADI type 4 is a susceptibility locus for rheumatoid arthritis (P = 0.000008). PADI4 was expressed in hematological and rheumatoid arthritis synovial tissues. We also identified a haplotype of PADI4 associated with susceptibility to rheumatoid arthritis that affected stability of transcripts and was associated with levels of antibody to citrullinated peptide in sera from individuals with rheumatoid arthritis. Our results imply that the PADI4 haplotype associated with susceptibility to rheumatoid arthritis increases production of citrullinated peptides acting as autoantigens, resulting in heightened risk of developing the disease.
PMID: 12833157 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード